



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

<b>NASDAQ: CLDX</b> <sup>1</sup>	
Last Trade:	2.97
Trade Time:	4:00 PM ET Oct 19, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.20 - 5.02
Volume	N/A
Market Cap. (\$M)	381.170
Shares Out (M)	128.340

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Oct 3, 2017*  
[Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs](#)
- Sep 22, 2017*  
[Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 12, 2017*  
[Celldex Announces Departure of Chief Medical Officer](#)
- Aug 23, 2017*  
[Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer](#)
- Aug 8, 2017*  
[Celldex Reports Second Quarter 2017 Results](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Second Quarter Financial Results](#)

- Mar 14, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Definitive Proxy Statement](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)